Format

Send to

Choose Destination
J Pediatr. 2004 Sep;145(3):340-5.

Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger.

Author information

1
Pediatric Liver Center and Section of Pediatric Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA.

Abstract

OBJECTIVE:

To test the hypothesis that there is an improved response to interferon in children with chronic hepatitis B (HBV) who are < or =5 years of age.

STUDY DESIGN:

Retrospective chart review of 22 consecutive children with chronic HBV (ages 17 months to 17 years; median, 83.9 months; 14 male, 8 female) treated with interferon-alpha2b.

RESULTS:

Ten patients (48%) responded to treatment [HBeAg (-), Anti-HBe (+), HBV DNA (-), HBsAg (+) and normal alanine aminotransferase/aspartate aminotransferase (ALT/AST) at 6 months after treatment], and 5 seroconverted HBsAg [above plus HBsAg negative and anti-HBs (+)]. Seven of 9 patients (78%) < or =5 years of age responded (5 cleared HBsAg). Three of 13 patients (23%) >5 years of age responded. Patient age at treatment was significantly lower in responders (63 +/- 70 months) versus nonresponders (104 +/- 55 months, P =.005). AST, ALT, and HBV DNA at the start of treatment were not different between responders and nonresponders or between patients < or =5 and >5 years old.

CONCLUSIONS:

Interferon treatment may be more effective in younger children with chronic hepatitis B.

PMID:
15343187
DOI:
10.1016/j.jpeds.2004.05.046
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center